Björn Pasternak

Björn Pasternak

Principal Researcher | Docent
Visiting address: ,
Postal address: K2 Medicin, Solna, K2 KEP Askling Pasternak, 171 77 Stockholm
Part of:

About me

  • 2002-2007 MD, Linköping University, Sweden
    2004-2008 PhD, Linköping University, Sweden
    2009-2016 Postdoc and Researcher, Statens Serum Institut, Copenhagen, Denmark
    2016- Senior/Principal Researcher, Karolinska Institutet
    2017- Associate Professor (docent), Karolinska Institutet

Research

  • Thriving on substantial expertise in large-scale register studies of adverse drug effects, we have the overall objective of using high-quality epidemiology to help inform evidence-based decisions in clinical practice. We have ongoing research programs in pediatric pharmacoepidemiology
  • safety and effectiveness of new diabetes drugs
  • and the area of expedited assessment of current drug safety concerns. My team’s scope is not limited to one single disease entity or therapeutic area
  • rather, we are in a constant process of seeking out and addressing emerging drug safety concerns with implications for clinical practice.

    TEAM MEMBERS
    * Peter Ueda [1], MD, PhD, assistant professor
    * Viktor Wintzell [2], PhD, coordinator/statistician
    * Henrik Svanström [3], PhD, senior statistician
    * Arvid Engström [4], MD, PhD-student
    * Carl-Emil Lim [5], MD/PhD-student
    * Laura Pazzagli [7], PhD, research specialist
    * Paulina J PhD, postdoc

    OUR RESEARCH IS AND HAS BEEN FUNDED BY
    * Swedish Research Council
    * Karolinska Institutet Faculty Funded Consolidator Grant
    * Swedish Cancer Society
    * Swedish Heart-Lung Foundation
    * Thrasher Research Foundation
    * Novo Nordisk Foundation
    * Nordic Cancer Union
    * Swedish Diabetes Foundation
    * Strategic Research Area Epidemiology (SfoEpi) at Karolinska Institutet
    * Karolinska Institutet Foundations and Funds
    * Stiftelsen Frimurare Barnhuset
    * Alzheimerfonden
    * Dr Margaretha Nilsson Stiftelse för Medicinsk Forskning
    * Åke Wibergs Stiftelse
    * Magnus Bergvalls Stiftelse

    SELECTED PUBLICATIONS
    Wintzell V, Svanström H, *Pasternak B. *Selection of comparator group in
    observational drug safety studies: alternatives to the active comparator new
    user design. *Epidemiology* 2022
    *Pasternak B*, Wintzell V, Melbye M, Eliasson B, Svensson AM, Franzén S,
    Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P. Use of
    sodium-glucose co-transporter 2 inhibitors and risk of serious renal events:
    Scandinavian cohort study. *BMJ* 2020
    *Pasternak B, *Ueda P, Eliasson B, Svensson AM, Franzén S,
    Gudbjörnsdottir S, Hveem K, Jonasson C, Wintzell V, Melbye M, Svanström H.
    Use of sodium glucose cotransporter 2 inhibitors and risk of major
    cardiovascular events and heart failure: Scandinavian register based cohort
    study. *BMJ *2019
    Svanström H, Ueda P, Melbye M, Eliasson B, Svensson AM, Franzén S,
    Gudbjörnsdottir S, Hveem K, Jonasson C, *Pasternak B. *Use of liraglutide
    and risk of major cardiovascular events: a register-based cohort study in
    Denmark and Sweden. *Lancet Diabetes Endocrinol* 2019
    Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S,
    Gudbjörnsdottir S, Hveem K, Jonasson C, *Pasternak B. *Sodium glucose
    cotransporter 2 inhibitors and risk of serious adverse events: nationwide
    register based cohort study. *BMJ* 2018
    *Pasternak B, *Inghammar M, Svanström H. Fluoroquinolone use and risk of
    aortic aneurysm and dissection: nationwide cohort study. *BMJ* 2018
    Scheller NM, *Pasternak B*, Mølgaard-Nielsen D, Svanström H, Hviid A.
    Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes. *New
    England Journal of Medicine* 2017
    Molgaard-Nielsen D, Svanstrom H, Melbye M, Hviid A, *Pasternak B*.
    Association Between Use of Oral Fluconazole During Pregnancy and Risk of
    Spontaneous Abortion and Stillbirth. *JAMA* 2016
    Scheller NM, Svanstrom H, *Pasternak B*, Arnheim-dahlstrom L, Sundstrom K,
    Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis
    and other demyelinating diseases of the central nervous system. *JAMA* 2015
    Scheller NM, *Pasternak B*, Svanstrom H, Hviid A. Quadrivalent human
    papillomavirus vaccine and the risk of venous thromboembolism. *JAMA* 2014
    Nyboe Andersen N, *Pasternak B*, Basit S, Andersson M, Svanstrom H, Caspersen
    S, et al. Association between tumor necrosis factor-α antagonists and risk
    of cancer in patients with inflammatory bowel disease. *JAMA* 2014
    Feenstra B, *Pasternak B*, Geller F, Carstensen L, Wang T, Huang F, et al.
    Common variants associated with general and MMR vaccine-related febrile
    seizures. *Nature genetics* 2014
    Molgaard-Nielsen D, *Pasternak B*, Hviid A. Use of oral fluconazole during
    pregnancy and the risk of birth defects. *New England Journal of Medicine*
    2013
    Hviid A, Melbye M, *Pasternak B*. Use of selective serotonin reuptake
    inhibitors during pregnancy and risk of autism. *New England Journal of
    Medicine* 2013
    Svanstrom H, *Pasternak B*, Hviid A. Use of azithromycin and death from
    cardiovascular causes. *New England Journal of Medicine* 2013
    *Pasternak B*, Svanstrom H, Melbye M, Hviid A. Association between oral
    fluoroquinolone use and retinal detachment. *JAMA* 2013
    *Pasternak B*, Svanstrom H, Molgaard-nielsen D, Melbye M, Hviid A.
    Metoclopramide in pregnancy and risk of major congenital malformations and
    fetal death. *JAMA* 2013
    *Pasternak B*, Svanstrom H, Hviid A. Ondansetron in pregnancy and risk of
    adverse fetal outcomes. *New England Journal of Medicine* 2013
    *Pasternak B*, Svanstrom H, Molgaard-nielsen D, Krause Tg, Emborg Hd, Melbye
    M, et al. Risk of adverse fetal outcomes following administration of a
    pandemic influenza A(H1N1) vaccine during pregnancy. *JAMA* 2012
    *Pasternak B*, Svanstrom H, Molgaard-nielsen D, Krause Tg, Emborg Hd, Melbye
    M, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy
    and risk of fetal death: cohort study in Denmark. *BMJ* 2012
    Svanstrom H, *Pasternak B*, Hviid A. Association of treatment with losartan
    vs candesartan and mortality among patients with heart failure. *JAMA* 2012
    *Pasternak B*, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in
    the first trimester of pregnancy and the risk of birth defects. *JAMA* 2010
    *Pasternak B*, Hviid A. Use of proton-pump inhibitors in early pregnancy and
    the risk of birth defects. *New England Journal of Medicine* 2010

    [1] http://ki.se/en/people/petjak
    [2] http://ki.se/en/people/viktwi
    [3] https://ki.se/en/people/henrsv
    [4] https://staff.ki.se/people/arengs
    [5] https://staff.ki.se/people/carlemil-lim
    [7] https://staff.ki.se/people/laura-pazzagli

Articles

All other publications

Employments

  • Principal Researcher, Department of Medicine, Karolinska Institutet, 2022-

Degrees and Education

  • Docent, Karolinska Institutet, 2017

News from KI

Events from KI